Logo image of PTCT

PTC THERAPEUTICS INC (PTCT) Stock Price, Quote, News and Overview

NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD

49.95  +0.43 (+0.87%)

After market: 49.95 0 (0%)

PTCT Quote, Performance and Key Statistics

PTC THERAPEUTICS INC

NASDAQ:PTCT (5/2/2025, 5:34:25 PM)

After market: 49.95 0 (0%)

49.95

+0.43 (+0.87%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High58.38
52 Week Low28.72
Market Cap3.94B
Shares78.87M
Float76.86M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-06 2025-05-06/amc
IPO06-20 2013-06-20


PTCT short term performance overview.The bars show the price performance of PTCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20

PTCT long term performance overview.The bars show the price performance of PTCT in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of PTCT is 49.95 USD. In the past month the price increased by 6.89%. In the past year, price increased by 51.32%.

PTC THERAPEUTICS INC / PTCT Daily stock chart

PTCT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.56B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About PTCT

Company Profile

PTCT logo image PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 939 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Company Info

PTC THERAPEUTICS INC

500 Warren Corporate Center Drive

WARREN NEW JERSEY 07080 US

CEO: Stuart W. Peltz

Employees: 1022

Company Website: https://www.ptcbio.com/

Investor Relations: https://ir.ptcbio.com/

Phone: 19082227000

PTC THERAPEUTICS INC / PTCT FAQ

What is the stock price of PTC THERAPEUTICS INC today?

The current stock price of PTCT is 49.95 USD. The price increased by 0.87% in the last trading session.


What is the ticker symbol for PTC THERAPEUTICS INC stock?

The exchange symbol of PTC THERAPEUTICS INC is PTCT and it is listed on the Nasdaq exchange.


On which exchange is PTCT stock listed?

PTCT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PTC THERAPEUTICS INC stock?

22 analysts have analysed PTCT and the average price target is 64.48 USD. This implies a price increase of 29.09% is expected in the next year compared to the current price of 49.95. Check the PTC THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PTC THERAPEUTICS INC worth?

PTC THERAPEUTICS INC (PTCT) has a market capitalization of 3.94B USD. This makes PTCT a Mid Cap stock.


How many employees does PTC THERAPEUTICS INC have?

PTC THERAPEUTICS INC (PTCT) currently has 1022 employees.


What are the support and resistance levels for PTC THERAPEUTICS INC (PTCT) stock?

PTC THERAPEUTICS INC (PTCT) has a support level at 49.51 and a resistance level at 57.15. Check the full technical report for a detailed analysis of PTCT support and resistance levels.


Is PTC THERAPEUTICS INC (PTCT) expected to grow?

The Revenue of PTC THERAPEUTICS INC (PTCT) is expected to decline by -11.27% in the next year. Check the estimates tab for more information on the PTCT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PTC THERAPEUTICS INC (PTCT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PTC THERAPEUTICS INC (PTCT) stock pay dividends?

PTCT does not pay a dividend.


When does PTC THERAPEUTICS INC (PTCT) report earnings?

PTC THERAPEUTICS INC (PTCT) will report earnings on 2025-05-06, after the market close.


What is the Price/Earnings (PE) ratio of PTC THERAPEUTICS INC (PTCT)?

PTC THERAPEUTICS INC (PTCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.01).


What is the Short Interest ratio of PTC THERAPEUTICS INC (PTCT) stock?

The outstanding short interest for PTC THERAPEUTICS INC (PTCT) is 7.13% of its float. Check the ownership tab for more information on the PTCT short interest.


PTCT Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to PTCT. When comparing the yearly performance of all stocks, PTCT is one of the better performing stocks in the market, outperforming 93.88% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PTCT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PTCT. Both the profitability and financial health of PTCT have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PTCT Financial Highlights

Over the last trailing twelve months PTCT reported a non-GAAP Earnings per Share(EPS) of -6.01. The EPS increased by 8.1% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -21.31%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-795.83%
Sales Q2Q%-30.58%
EPS 1Y (TTM)8.1%
Revenue 1Y (TTM)-13.98%

PTCT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to PTCT. The Buy consensus is the average rating of analysts ratings from 22 analysts.

For the next year, analysts expect an EPS growth of 48.08% and a revenue growth -11.27% for PTCT


Ownership
Inst Owners102.05%
Ins Owners0.74%
Short Float %7.13%
Short Ratio5.55
Analysts
Analysts74.55
Price Target64.48 (29.09%)
EPS Next Y48.08%
Revenue Next Year-11.27%